Overview

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Status:
Recruiting

Trial end date:
2024-12-30

Target enrollment:

Participant gender:

Summary

Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

Phase:

Phase 3

Details

Lead Sponsor:

Mirati Therapeutics Inc.

Treatments:

Adagrasib
Cetuximab